Toronto-based AI drug discovery company BenchSci has raised CAD 95 million (USD 70 million) in a Series D funding round led by Generation Investment Management, with participation from existing investors iNovia Capital and TCV, among others.
The proceeds will be directed toward further developing and expanding the capabilities of the company’s proprietary AI platform, ASCEND. The platform, which is currently being used by over 50,000 scientists, is reportedly capable of expediting the pre-clinical testing of novel drug targets by reducing trial-and-error and identifying potential problems sooner.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.